3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Completed
3
Active not recruiting
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Conditions
Pancreatic Neoplasms
71
Breast Neoplasms
45
Neoplasms
29
Carcinoma, Non-Small-Cell Lung
29
Triple Negative Breast Neoplasms
21
Neoplasm Metastasis
14
Adenocarcinoma
13
Squamous Cell Carcinoma of Head and Neck
8
Lung Neoplasms
8
Colorectal Neoplasms
8
Melanoma
7
Carcinoma
7
Head and Neck Neoplasms
6
Digestive System Neoplasms
6
Cholangiocarcinoma
6
Small Cell Lung Carcinoma
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pancreatic Diseases
5
Pancreatic Adenocarcinoma
5
Ovarian Neoplasms
5
Digestive System Diseases
5
Carcinoma, Pancreatic Ductal
5
Stomach Neoplasms
4
Sarcoma
4
Recurrence
4
Neoplasms by Site
4
Gallbladder Neoplasms
4
Fallopian Tube Neoplasms
4
Endocrine Gland Neoplasms
4
Carcinoma, Squamous Cell
4
Interventions
Paclitaxel
6
Carboplatin
6
Radiotherapy
5
Chemotherapy, Adjuvant
5
Cyclophosphamide
4
Trastuzumab
3
Tamoxifen
3
Letrozole
3
Doxorubicin
3
Brachytherapy
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
pertuzumab
2
Surgical Procedures, Operative
2
Radiotherapy, Conformal
2
Magnetic Resonance Spectroscopy
2
Epirubicin
2
talimogene laherparepvec
1
sargramostim
1
palbociclib
1
ferric carboxymaltose
1
atezolizumab
1
atamestane
1
aldesleukin
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
VPS Coriolus versicolor extract
1
Toremifene
1
Thiotepa
1
Therapeutics
1
Reverse Transcriptase Polymerase Chain Reaction
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Ductal, Breast
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT02620280
2024-03-06
NeoTRIPaPDL1
Fondazione Michelangelo
Phase 3
Completed
278 enrolled
NCT02682693
2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2
Completed
780 enrolled
NCT01583426
2020-08-06
GeparSepto
GBG Forschungs GmbH
Phase 3
Completed
1,229 enrolled